- Home
- RAMP vs PVLA Comparison
RAMP vs PVLA Comparison
Compare RAMP & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RAMP | PVLA |
|---|---|---|
| Founded | 2018 | 2015 |
| Country | United States | United States |
| Employees | N/A | 14 |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.6B |
| IPO Year | 1994 | N/A |
Fundamental Metrics
Financial Performance| Metric | RAMP | PVLA |
|---|---|---|
| Price | $29.73 | $114.82 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 15 |
| Target Price | $35.60 | ★ $171.87 |
| AVG Volume (30 Days) | ★ 432.0K | 182.3K |
| Earning Date | 05-20-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.14 | N/A |
| Revenue | ★ $745,580,000.00 | N/A |
| Revenue This Year | $11.18 | N/A |
| Revenue Next Year | $9.09 | $104,350.18 |
| P/E Ratio | $25.51 | ★ N/A |
| Revenue Growth | ★ 13.02 | N/A |
| 52 Week Low | $21.71 | $20.20 |
| 52 Week High | $35.20 | $151.18 |
Technical Indicators
Market Signals| Indicator | RAMP | PVLA |
|---|---|---|
| Relative Strength Index (RSI) | 55.24 | 41.77 |
| Support Level | $26.47 | $109.68 |
| Resistance Level | $30.31 | $114.69 |
| Average True Range (ATR) | 0.89 | 7.39 |
| MACD | -0.15 | -1.33 |
| Stochastic Oscillator | 59.88 | 15.51 |
Price Performance
Historical ComparisonAbout RAMP LiveRamp Holdings Inc.
LiveRamp Holdings Inc is a technology company that helps companies build enduring brand and business value by collaborating responsibly with data. A groundbreaking leader in consumer privacy, data ethics, and foundational identity, LiveRamp offers a connected customer view with clarity and context while protecting brand and consumer trust. The Company provides a data collaboration platform, essentially acting as a data collaboration hub where businesses can securely share and manage first-party consumer data with trusted partners while prioritizing data privacy and ethics.
About PVLA Palvella Therapeutics Inc.
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.